Surging global demand for GLP-1 receptor agonists has transformed pharmaceutical capital expenditure strategy. Bottlenecks in sterile fill-finish capacity continue to constrain market growth for metabolic health therapies.
Fill-Finish Infrastructure Deficit
Contract Development and Manufacturing Organizations are operating at maximum capacity. Drugmakers are aggressively purchasing existing manufacturing facilities rather than building greenfield plants, shortening deployment timelines by up to three years.
Next-Gen Peptide Pipeline
Acquisitions are shifting toward oral delivery platforms and long-acting peptide formulations. Companies targeting monthly or quarterly dosage intervals are drawing premium valuations from tier-one pharma buyers.